Missouri Senators approve bill to legalize psilocybin therapy for veterans

A Missouri Senate Committee has approved the Republican-led bill that would legalize medical use of Psilocybin for veterans , and fund research exploring the therapeutic potential.

The Senate Emerging Issues Committee approved the bill from Sen. Holly Thompson Rehder, R., with some amendments on Tuesday.

The bill, as revised, would allow veterans of the military who are 21 years old and have been diagnosed with a qualifying disorder such as Post-Traumatic Stress Disorder (PTSD) or Substance Use Disorders to access psilocybin that has been laboratory tested. In committee, the veteran requirement was introduced.

Participants would have to be involved in, or seek to participate in, a psychedelic study to qualify for legal protections.

Patients are required to give the Department of Mental Health of their state information on their diagnosis, who will administer psilocybin, and the location and time of treatment sessions. According to the original proposal, this oversight would have been a responsibility of the Department of Health and Senior Services.

In committee, the bill was amended to include additional requirements to become a facilitator that could administer psychedelics. It also now includes training requirements for these professionals. The substitute version contains modified language which calls for patients to enroll in studies more generally, rather than specifying they are clinical trials.

Psilocybin was only allowed to be used for a maximum period of one year. The amount of psychedelics that could be used during this treatment is limited to 150 milligrams. However, patients who qualify could also be approved to continue the treatment over subsequent periods of one year.

All regulators, physicians, and officials of state agencies would be protected from any legal consequences relating to activities made legal under the law.

The legislation also calls on DMH to grant $3 million to support “research into the use and effectiveness of psilocybin” – a $1,000,000 increase over the original bill. The bill has also been revised so that the funding must come from the state’s opioid addiction treatment fund.

This measure expands the Right to Try law to include people who are suffering from severe debilitating or life-threatening conditions, as well as those with terminal illness. The measure would remove language that prohibited the use of Schedule I substances, a first step towards potentially opening access to other substances like additional psychedelics.

It also states that “an institution or higher education in the state of New York, or contract research organisations conducting trials approved by United States Food and Drug Administration” can conduct psilocybin-related research.

The bill SB 886 takes its lead from another House bill that was advanced to the floor last year , but not ultimately passed.

Last month, the House Veterans Committee heard about a current House companion bill to the psilocybin legislation this session. The bill was not amended or voted on.

In this session, a growing number of state legislatures are working on psychedelic reform legislation with an emphasis on research and therapeutic accessibility.

Marijuana Moment tracks more than 1,000 cannabis and drug policy bills that have been introduced in state legislatures, and Congress. Patreon supporters who pledge at least $25/month gain access to our interactive charts, maps and hearing calendar.

Discover more about our marijuana bills tracker. Become a Patreon supporter to gain access.

—

Connecticut legislators, for example, have revived a campaign to decriminalize possession of low-level psilocybin despite recent indications from the Governor’s Office that they are concerned about the reform.

Recently, the governor of New Mexico endorsed a newly passed resolution that requested state officials to research the therapeutic potential psilocybin as well as explore the creation a regulatory framework for providing access to psychedelics.

A senator from Illinois introduced a bill to legalize and regulate access to psilocybin at service centers within the state, where adults can use the psychedelic under supervision. The program will eventually include mescaline and ibogaine.

The bill was sent to the Arizona Senate floor after a second committee, which is bipartisan, approved it. It would legalize the establishment of psilocybin services centers, where individuals could obtain the psychedelic under medical supervision.

In anticipation of a federal legalization, an Alaska Senate Committee advanced a bill earlier this month that would create a task force to study how to license psychedelic assisted therapy.

Hawaii lawmakers are also advancing a bill which would give some legal protections for patients who engage in psilocybin assisted therapy after a doctor’s approval.

A Republican-led Indiana House committee has approved a bill to fund clinical trials for psilocybin, which was already passed by the Senate.

Recently, bipartisan California legislators introduced a bill that would legalize psychedelic services centers, where adults aged 21 and over could have access to psilocybin MDMA mescaline DMT and other psychedelics in a supervised environment , with trained facilitators.

Last month, a joint Nevada legislative committee heard expert testimony and public testimony about the therapeutic potential for substances such as psilocybin. Law enforcement officials also expressed their concerns about legalization. However, there was a notable acknowledgment that reforms could be implemented including rescheduling.

The Governor of Massachusetts recently promoted the testimony from activists who spoke out in support of her veterans’ bill. This bill would, among other things, create a work group for psychedelics to investigate the therapeutic potentials of substances like psilocybin.

New York legislators have introduced a bill to create an pilot program for psilocybin treatment to 10,000 people. The focus is on veterans and first responders.